Cardiovascular News’ Post

Flashback Friday: EARLY TAVR Trial – A Shift in Managing Aortic Stenosis The EARLY TAVR trial, featured at TCT 2024 and led by Dr. Philippe Généreux, underscores the benefits of proactive intervention for asymptomatic severe aortic stenosis (AS). Findings show that early TAVR (Transcatheter Aortic Valve Replacement) significantly reduces complications like stroke and unplanned hospitalizations, while enhancing quality of life and preserving cardiac health. At AccurKardia, proactive care is central to our mission of improving outcomes and saving lives. Our AK-AVS™ technology (FDA Breakthrough Device Designation, October 2024) leverages AI-driven ECG analysis to identify AS early, supporting timely interventions that help prevent the rapid health declines often seen in AS patients under a "wait-and-see" approach. Learn more about the EARLY TAVR study: https://lnkd.in/e5Js6yBK #AorticStenosis #TAVR #ProactiveCare #BetterOutcomes #Innovation

It's time to make diffrence for Women The SMART Trial was a prospective, multicenter, randomized controlled trial conducted to understand how valve design differences between the Medtronic self-expandable (SE) Evolut™ platform and Edwards Lifesciences balloon-expandable (BE) SAPIEN™* transcatheter aortic valve replacement system affect treatment of small aortic annulus (≤ 430 mm2) patients with symptomatic, severe native-aortic stenosis (87% enrolled in this trail were Women). One year late-breaking data confirm that these contemporary TAVs behave differently in this patient group, providing physicians with crucial insights to tailor treatment decisions according to individual patient needs. #SMARTtrial #medtronic #structuralheart

👍 Foldax Inc. reported positive safety results in a trial of its TRIA mitral surgical heart valve, designed using a novel polymer material for the treatment of conditions including rheumatic heart disease. Congratulations to Frank Maguire and the rest of the team for the encouraging results. 👏 🔗Read more: https://lnkd.in/dGTVDF27 📰 Follow Guided Solutions to receive the latest #MedTech news daily and subscribe to our weekly newsletter: https://lnkd.in/dnwRT6qy #MedicalDevices #MedicalDevice #MedicalEquipment #Medicine #HealthTech #Surgeons #GuidedSolutions

RADPAD Reduces Radiation by More Than 68% During Complex PCI Procedures! A study published in the American Journal of Cardiology investigated the effectiveness of RADPAD® Radiation Protection Shields in minimizing radiation exposure for interventional cardiologists performing complex PCI procedures. The study focused on 60 patients undergoing complex PCI, including procedures with: - Rotational atherectomy - Multivessel PCI - Chronic total occlusions (CTOs) RADPAD® significantly reduced radiation exposure to operators compared to the control group, especially when considering radiation dose relative to procedure duration. The study found a significant difference in the rate of radiation dose increase between the groups: RADPAD Group: Slope = 1.44 No RADPAD Group: Slope = 4.60 This translates to a slower increase in radiation dose per minute of fluoroscopy for operators using RADPAD®. Choose RADPAD®, backed by more than 40 clinical studies, for a safer work environment and continued dedication to patient care. #RADPAD #RadiationProtection #Cardiology #PCI #MedEd #HealthcareSafety 

Yesterday, we faced a complex case of total thrombotic occlusion of the RCA. Despite multiple attempts with traditional aspiration catheters, we encountered significant resistance due to heavy thrombus burden. We successfully navigated this challenge by utilizing the Penumbra catheter. By carefully clearing the thrombus from the catheter, we were able to restore blood flow and successfully stent the RCA with a 3.5x18mm Promus Elite stent. This case highlights the importance of having advanced tools like the Penumbra catheter at our disposal. It allows us to overcome challenging situations and improve patient outcomes. #CCL #Cathlab #PCI #penumbra #Coronary #interventionalcardiology #cardiology #medicaltechnology #hearthealth #healthcare Penumbra, Inc. Penumbra Vascular

DEDICATE-DZKH6 presented at the ACC.24 meeting and was promising. TAVR was found to bring no increased risks and was associated with substantially decreased rates of death or stroke at one year in low-risk patients, compared with surgical aortic valve replacement (SAVR). We may still need long-term data regarding the durability of the TAVR valves especially low risk patient population. Heart team approach still is the recommended way to decide TAVR vs SAVR in a patient centric approach, which should take patient preferences into consideration

The #SMARTtrial 1-year outcomes are here! Due to its focus on patients with small annuli, 87% of those enrolled in this late-breaking trial were women. Explore this revolutionary data and see how Evolut™ #TAVR makes a big difference for women with #AorticStenosis¹: https://bit.ly/3J9ttn3 Risk Info: https://bit.ly/3J9tszv TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.

Boston Scientific received CE Mark for its Acurate Prime Aortic Valve System. The TAVR System is set to enhance precision and efficiency in transcatheter aortic valve replacement (TAVR) procedures. This holds notable implications for healthcare: 1. 𝐄𝐱𝐩𝐚𝐧𝐝𝐞𝐝 𝐀𝐜𝐜𝐞𝐬𝐬: This system could make advanced cardiovascular care more accessible to patients across Europe, particularly those who might not have previously qualified for traditional surgical interventions. 2. 𝐈𝐦𝐩𝐫𝐨𝐯𝐞𝐝 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐎𝐮𝐭𝐜𝐨𝐦𝐞𝐬: With better precision in valve placement, patients may experience fewer complications and faster recoveries. 3. 𝐐𝐮𝐢𝐜𝐤𝐞𝐫, 𝐂𝐨𝐧𝐭𝐫𝐨𝐥𝐥𝐞𝐝 𝐃𝐞𝐩𝐥𝐨𝐲𝐦𝐞𝐧𝐭: Streamlined device preparation and advanced technology enable faster, more precise valve deployment, potentially reducing procedure time and improving efficiency. 4. 𝐌𝐢𝐧𝐢𝐦𝐚𝐥𝐥𝐲 𝐈𝐧𝐯𝐚𝐬𝐢𝐯𝐞 𝐂𝐚𝐫𝐞: This system's availability could support the increasing demand for minimally invasive heart valve treatments, and alleviate pressure on traditional surgical resources. #BostonScientific #TAVR #Cardiovascular #Healthcareinnovation #Medicaldevices #Cardiovascularcare #Healthcareaccess

PET/CT is poised to become a key tool for imaging the coronary arteries – a clinical imaging exam that can reveal early warning signs of fatal conditions when patients present with symptoms of chest pain, experts say. The “hybrid” scan – which combines molecular PET and anatomical CT images – may have its highest potential in visualizing early signs of so-called “perfusion deficits” (regions of obstructed blood flow). https://ow.ly/ybaX50Rfh69 #PET #CT #PETCT

Yesterday’s #ClinicalChallenge question was: True or false? In patients with severe aortic stenosis, long-term mortality rates are higher with transcatheter aortic valve implantation (TAVI) compared with surgical aortic valve replacement (SAVR). The answer is: False. In a recent trial in 280 patients with severe aortic stenosis who were randomly assigned to receive a bioprosthetic valve via transcatheter implantation or surgical replacement, mortality rates at 10 years were similar between the two groups. View the related What's New topic in #UpToDate: https://ow.ly/yalK50TYlhr #cardiology #meded